Intraperitoneal administration of paclitaxel and oral S-1 for a patient with peritoneal dissemination and hydronephrosis due to advanced gastric cancer

Gastric Cancer

Volumn 10, Issue 4, 2007, Pages 251-255

  Tamura, Shigeyuki ^a   Miki, Hirofumi ^a   Nakata, Ken ^a   Takiuchi, Daisuke ^a   Okada, Kaoru ^a   Nakahira, Shin ^a   Okamura, Shu ^a   Sugimoto, Keishi ^a   Tomita, Naohiro ^a   Takatsuka, Yuichi ^a  

^a KANSAI ROSAI HOSPITAL   (Japan)

Author keywords

Advanced gastric cancer; Intraperitoneal chemotherapy; Paclitaxel; Peritoneal dissemination; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; HISTAMINE H2 RECEPTOR ANTAGONIST; PACLITAXEL;

ADULT; ADVANCED CANCER; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DUODENUM CANCER; GASTRECTOMY; HUMAN; HUMAN TISSUE; HYDRONEPHROSIS; LAPAROSCOPY; LIVER METASTASIS; LYMPH NODE DISSECTION; MALE; MULTIPLE CYCLE TREATMENT; PERITONEAL DISEASE; PERITONEAL DISSEMINATION; PRIORITY JOURNAL; QUALITY OF LIFE; STOMACH CANCER; TUMOR BIOPSY;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG COMBINATIONS; HUMANS; HYDRONEPHROSIS; INFUSIONS, PARENTERAL; LIVER NEOPLASMS; MALE; OXONIC ACID; PACLITAXEL; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS; TEGAFUR;

EID: 37349090574     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-007-0431-x     Document Type: Article

References (18)

1. Yonemura Y, Sawa T, Kinoshita K, Matsuki N, Fushida S, Tanaka S, et al. Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg 1993;17:256-62.
2. Sugerbaker PH, Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology 2000;58:96-107.
3. Fujimoto S, Takahashi M, Kobayashi K, Kure M, Mutou T, Masaoka H, et al. Relation between clinical and histologic outcome of intraperitoneal hyperthermic perfusion for patients with gastric cancer and peritoneal metastasis. Oncology 1993;50:338-43.
4. Nomura E, Niki M, Fujii K, Shinohara H, Nishiguchi K, Sonoda T. Efficacy of intraperitoneal and intravenous chemotherapy and left upper abdominal evisceration for advanced gastric cancer. Gastric Cancer 2001;4:75-82.
5. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548-57.
6. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study on novel oral fluoropyrimidine anticancer drug S-1 (IM Tegafur-0.4M Gimestat-1M Otastat Potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-20.
7. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000;58:191-7.
8. Mori T, Fujiwara Y, Yano M, Tamura S, Yasuda T, Takiguchi S, et al. Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-fluorouracil. Oncology 2003;64:176-82.
9. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW. Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res 1988;48:4093-100.
10. Markman M, Rowinsky E, Harkes T, Reichman B, Jones W, Lewis JL Jr, et al. Phase I trial of intraperitoneal Taxol: a Gynecoloic Oncology Group Study. J Clin Oncol 1992;10:1485-91.
11. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 2nd English ed. Gastric Cancer 1998;1:25-30.
12. Konishi T, Hiraishi M, Mafune K, Miyama T, Hirata T, Mori K, et al. Therapeutic efficacy and toxicity of sequential methotrexate and 5-fluorouracil in gastric cancer. Anticancer Res 1994: 14:1277-80.
13. Tahara M, Ohotsu A, Boku N, Nagashima F, Muto M, Sano Y, et al. Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study. Gastric Cancer 2001;4:212-8.
14. Osugi H, Takada N, Takemura M, Kaseno S, Lee S, Ueno M, et al. Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination. Oncol Rep 2002;9:811-5.
15. Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Oncol 1995;13:2961-7.
16. Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC. Phase II trial of intraperitoneal Taxol in carcinoma of the ovary, tube, and peritoneum: a Gynecoloic Oncology Group Study. J Clin Oncol 1998;16: 1485-91.
17. Fushida S, Furui N, Kinami S, Ninomiya I, Fujimura T, Nishimura G, et al. Pharmacologic study of intraperitoneal paclitaxel in gastric cancer patients with peritoneal dissemination (in Japanese). Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 2002;29:2164-7.
18. Yonemura Y, Endou Y, Bando E, Kuno K, Kawamura T, Kimura M, et al. Effect of intraperitoneal administration of docetaxel on peritoneal dissemination of gastric cancer. Cancer Lett 2004;210:189-96.